Our Take
In vivo CAR-T remains unproven in humans but addresses a real manufacturing bottleneck: current ex vivo therapies cost $400K–$500K per patient and take 3–6 weeks, pricing out most patients and leaving others to worsen while waiting.
Why it matters
Cell therapy is locked behind manufacturing capacity and cost. If any of these eight companies clears an in vivo candidate, it signals that genetically engineered T cells can be made in the patient's bloodstream, not in a cleanroom, opening access to a patient population currently shut out.
Do this week
Biotech investors: track LB2501 (Legend Biotech) and UB-VV111 (Umoja) for Phase 1 readouts this year—both have disclosed efficacy and safety data that will set the bar for in vivo safety profiles.
Eight in vivo CAR-T programs advance toward clinical proof
In vivo CAR-T therapy flips the manufacturing model. Instead of extracting a patient's T cells, engineering them in a lab over 3–6 weeks, and reinfusing them (current standard), in vivo approaches inject a delivery vehicle directly into the bloodstream. The vehicle finds circulating T cells, enters them, and delivers genetic instructions to make a CAR inside the body.
The result: no cell manufacturing, no lymphodepleting chemotherapy required, and weeks of wait time eliminated. No in vivo CAR-T has yet won FDA approval. But eight companies are now in preclinical or clinical stages.
Legend Biotech, the New Jersey-based maker of the approved ex vivo therapy Carvykti, reported Phase 1 data this week for LB2501, a dual-targeting in vivo candidate for non-Hodgkin lymphoma. At the second dose level, 100% of patients showed an overall response rate, 83.3% achieved complete response, and there were no dose-limiting toxicities or ICANS (per company announcement at the European Hematology Association conference in June 2026). Umoja Biopharma, based in Seattle and backed by a $100 million Series C closed in January 2025, has its lead candidate UB-VV111 in clinical trials for large B-cell lymphoma and chronic lymphocytic leukemia, granted FDA fast-track status in September 2024.
Minnesota-based Vyriad, founded by Mayo Clinic scientists in 2015, recently secured $25 million in Series B funding (December 2025) for VV169, targeting multiple myeloma. Preclinical data showed complete tumor clearance in all treated mice within 28 days. German biotech CPTx uses immune-silent single-stranded DNA vectors instead of viral integration, presenting preclinical work at the American Society of Gene & Cell Therapy annual meeting in May 2026. Strand Therapeutics, founded by MIT synthetic biology researchers and backed by over $250 million raised (including a $153 million Series B in August 2025), is developing STX-005, a circular mRNA-based in vivo CAR-T for autoimmune disease and blood cancer. New York-based Alaya.bio, founded in 2022 and funded with $6.5 million in equity plus $4 million non-dilutive grants, has partnered with Nona Biosciences since 2024 on a CD19-targeting in vivo construct.
Manufacturing capacity and cost are the real barriers
Current ex vivo CAR-T therapy costs $400,000 to $500,000 per treatment (company-reported pricing). Production requires specialized facilities, takes 3–6 weeks per patient, and mandates lymphodepleting chemotherapy to make biological room for the engineered cells. Many patients are ineligible. Others' conditions worsen during the manufacturing window.
If in vivo approaches work, the supply chain disappears. A single injection, no manufacturing, no chemotherapy, faster response. The field shifts from a batch-manufacturing model to a point-of-care delivery model. That is a structural change to access and economics, not an incremental improvement to existing infrastructure.
The clinical data so far—particularly Legend's 100% response rate with zero dose-limiting toxicity—suggests the safety bar for in vivo can be met. Durability and long-term survival data are still pending across all programs.
Clinicians and payers should watch Phase 1 completions
LB2501 and UB-VV111 are the nearest to Phase 2 readiness. Both have disclosed response rates and safety signals. Payers should prepare cost models assuming $100K–$200K per dose if manufacturing and delivery scale, though no final pricing exists. Clinicians should expect rapid updates on response durability and any delayed toxicities over the next 12 months. If any of these eight advances to Phase 2 with maintained efficacy and acceptable safety, hospital CAR-T programs will face pressure to adopt in vivo candidates as soon as they clear trial.